Targeting EBNA1 to fight cancers linked to the EBV virus
Drugging EBNA1 to Treat EBV-Associated Cancers
['FUNDING_R01'] · WISTAR INSTITUTE · NIH-11118947
This research is creating new medicines that specifically target a protein called EBNA1, which is essential for certain cancers caused by the Epstein-Barr virus (EBV) to grow.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WISTAR INSTITUTE (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11118947 on ClinicalTrials.gov |
What this research studies
Many cancers are linked to the Epstein-Barr virus (EBV), and currently, there are no specific treatments for these EBV-positive tumors. This project focuses on a viral protein called EBNA1, which these cancers need to survive and grow. We are developing special small molecules that attach to EBNA1, stopping it from helping the cancer cells thrive. Our goal is to understand exactly how these molecules work and to make them even more powerful, potentially by combining them with existing chemotherapy or designing new, highly effective drugs.
Who could benefit from this research
Good fit: This foundational research is for patients with EBV-associated cancers who may benefit from future clinical trials of these new targeted therapies.
Not a fit: Patients whose cancers are not associated with the Epstein-Barr virus would likely not benefit from therapies developed through this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to the first targeted treatments for EBV-associated cancers, offering new hope for patients.
How similar studies have performed: While EBNA1 has been a challenging target, this project builds on initial success in developing selective molecules that bind to EBNA1.
Where this research is happening
PHILADELPHIA, UNITED STATES
- WISTAR INSTITUTE — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MESSICK, TROY E — WISTAR INSTITUTE
- Study coordinator: MESSICK, TROY E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents